Dual-targeting triplebody 33-3-19 mediates selective lysis of biphenotypic CD19+ CD33+ leukemia cells.
about
CD20 monoclonal antibody targeted nanoscale drug delivery system for doxorubicin chemotherapy: an in vitro study of cell lysis of CD20-positive Raji cellsRecent developments in immunotherapy of acute myeloid leukemia.CD19-specific triplebody SPM-1 engages NK and γδ T cells for rapid and efficient lysis of malignant B-lymphoid cells.Dual-targeting triplebody 33-16-123 (SPM-2) mediates effective redirected lysis of primary blasts from patients with a broad range of AML subtypes in combination with natural killer cells
P2860
Dual-targeting triplebody 33-3-19 mediates selective lysis of biphenotypic CD19+ CD33+ leukemia cells.
description
2016 nî lūn-bûn
@nan
2016年の論文
@ja
2016年論文
@yue
2016年論文
@zh-hant
2016年論文
@zh-hk
2016年論文
@zh-mo
2016年論文
@zh-tw
2016年论文
@wuu
2016年论文
@zh
2016年论文
@zh-cn
name
Dual-targeting triplebody 33-3 ...... ic CD19+ CD33+ leukemia cells.
@en
type
label
Dual-targeting triplebody 33-3 ...... ic CD19+ CD33+ leukemia cells.
@en
prefLabel
Dual-targeting triplebody 33-3 ...... ic CD19+ CD33+ leukemia cells.
@en
P2093
P2860
P356
P1433
P1476
Dual-targeting triplebody 33-3 ...... ic CD19+ CD33+ leukemia cells.
@en
P2093
Claudia C Roskopf
Fuat S Oduncu
Georg H Fey
Nadja C Fenn
Sebastian Kobold
Todd A Braciak
P2860
P304
22579-22589
P356
10.18632/ONCOTARGET.8022
P407
P577
2016-03-10T00:00:00Z